The effect of neoadjuvant Imatinib therapy on outcome and survival after rectal gastrointestinal stromal tumour
- 6 October 2010
- journal article
- research article
- Published by Wiley in Colorectal Disease
- Vol. 13 (10) , 1110-1115
Abstract
Aim The study aimed to characterize the pathological and clinical response of rectal gastrointestinal stromal tumours (GISTs) to neoadjuvant Imatinib. Method The medical records of patients with rectal GISTs who were diagnosed and treated in five medical centres in Israel between January 2002 and January 2009 were retrospectively examined. Twelve patients who fulfilled the inclusion criteria of nonmetastatic rectal GIST for which preoperative neoadjuvant treatment with Imatinib was considered were suitable for enrollment. Results Of the 12 patients, nine received neoadjuvant treatment with Imatinib. The three patients who had immediate surgery were excluded. There were five men and four women with a median age of 63 years and a median follow up of 32 months. All tumours were located in the lower two-thirds of the rectum. One patient had a complete clinical response, six had a partial response and two had stable disease. Seven patients subsequently underwent surgery; six had an R0 resection and one had an R1 resection. Three patients had recurrence. There was no disease-related mortality. The reduction in both tumour size and mitotic activity during preoperative Imatinib therapy was significant. Conclusion Preoperative Imatinib therapy can shrink large rectal GISTs, improving the chances of successful radical surgery and decreasing the risk of considerable morbidity.Keywords
This publication has 27 references indexed in Scilit:
- The Epidemiology of Malignant Gastrointestinal Stromal Tumors: An Analysis of 1,458 Cases from 1992 to 2000American Journal of Gastroenterology, 2005
- Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor siteLaboratory Investigation, 2004
- Gene Expression in Gastrointestinal Stromal Tumors Is Distinguished by KIT Genotype and Anatomic SiteClinical Cancer Research, 2004
- Diagnosis of gastrointestinal stromal tumors: A consensus approachHuman Pathology, 2002
- Gastrointestinal Stromal Tumors, Intramural Leiomyomas, and Leiomyosarcomas in the Rectum and AnusAmerican Journal of Surgical Pathology, 2001
- Immunohistochemical Spectrum of GISTs at Different Sites and Their Differential Diagnosis with a Reference to CD117 (KIT)Laboratory Investigation, 2000
- Prognosis of Gastrointestinal Smooth-Muscle (Stromal) TumorsAmerican Journal of Surgical Pathology, 1999
- Immunophenotype, proliferation, DNA ploidy, and biological behavior of gastrointestinal stromal tumors: A multivariate clinicopathologic studyHuman Pathology, 1998
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998
- Differentiation and Risk Assessment of Gastrointestinal Stromal TumorsAmerican Journal of Clinical Pathology, 1995